Agency for Science, Technology and Research

About: Agency for Science, Technology and Research is a government organization based out in Singapore, Singapore. It is known for research contribution in the topics: Catalysis & Population. The organization has 16013 authors who have published 24427 publications receiving 832302 citations. The organization is also known as: A*STAR & A-Star.

LIME: Low-Light Image Enhancement via Illumination Map Estimation

Abstract: When one captures images in low-light conditions, the images often suffer from low visibility. Besides degrading the visual aesthetics of images, this poor quality may also significantly degenerate the performance of many computer vision and multimedia algorithms that are primarily designed for high-quality inputs. In this paper, we propose a simple yet effective low-light image enhancement (LIME) method. More concretely, the illumination of each pixel is first estimated individually by finding the maximum value in R, G, and B channels. Furthermore, we refine the initial illumination map by imposing a structure prior on it, as the final illumination map. Having the well-constructed illumination map, the enhancement can be achieved accordingly. Experiments on a number of challenging low-light images are present to reveal the efficacy of our LIME and show its superiority over several state-of-the-arts in terms of enhancement quality and efficiency.

MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation

Abstract: MicroRNAs (miRNAs) are short RNAs that direct messenger RNA degradation or disrupt mRNA translation in a sequence-dependent manner. For more than a decade, attempts to study the interaction of miRNAs with their targets were confined to the 3' untranslated regions of mRNAs, fuelling an underlying assumption that these regions are the principal recipients of miRNA activity. Here we focus on the mouse Nanog, Oct4 (also known as Pou5f1) and Sox2 genes and demonstrate the existence of many naturally occurring miRNA targets in their amino acid coding sequence (CDS). Some of the mouse targets analysed do not contain the miRNA seed, whereas others span exon-exon junctions or are not conserved in the human and rhesus genomes. miR-134, miR-296 and miR-470, upregulated on retinoic-acid-induced differentiation of mouse embryonic stem cells, target the CDS of each transcription factor in various combinations, leading to transcriptional and morphological changes characteristic of differentiating mouse embryonic stem cells, and resulting in a new phenotype. Silent mutations at the predicted targets abolish miRNA activity, prevent the downregulation of the corresponding genes and delay the induced phenotype. Our findings demonstrate the abundance of CDS-located miRNA targets, some of which can be species-specific, and support an augmented model whereby animal miRNAs exercise their control on mRNAs through targets that can reside beyond the 3' untranslated region.

CO2 capture by solid adsorbents and their applications: current status and new trends

Abstract: In the last few years there has been a rapid growth in governmental funding and research activities worldwide for CO2 capture, storage and utilization (CSU), due to increasing awareness of the link between CO2 accumulation in the atmosphere and global warming. Among the various technologies and processes that have been developed and are emerging for CSU of CO2, solid CO2-adsorbents are widely applied. In this review, these solid CO2-adsorbents are classified into three types according to their sorption/desorption temperatures: low-, intermediate- and high-temperature adsorbents with temperatures ranging from below 200 °C, between 200–400 °C and above 400 °C, respectively. For each type of solid CO2-adsorbent, the synthesis, interaction mechanism with CO2 and sorption performance, potential applications and problems are reviewed. In the last section, several representative CO2-sorption-enhanced catalytic reactions are discussed. It is expected that this review will not only summarize the main research activities in this area, but also find possible links between fundamental studies and industrial applications.

Genome-wide analysis of mammalian promoter architecture and evolution

Abstract: Mammalian promoters can be separated into two classes, conserved TATA box-enriched promoters, which initiate at a well-defined site, and more plastic, broad and evolvable CpG-rich promoters. We have sequenced tags corresponding to several hundred thousand transcription start sites (TSSs) in the mouse and human genomes, allowing precise analysis of the sequence architecture and evolution of distinct promoter classes. Different tissues and families of genes differentially use distinct types of promoters. Our tagging methods allow quantitative analysis of promoter usage in different tissues and show that differentially regulated alternative TSSs are a common feature in protein-coding genes and commonly generate alternative N termini. Among the TSSs, we identified new start sites associated with the majority of exons and with 3' UTRs. These data permit genome-scale identification of tissue-specific promoters and analysis of the cis-acting elements associated with them.

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

Abstract: BackgroundNon–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies. MethodsIn this phase 1 study, we administered oral ceritinib in doses of 50 to 750 mg once daily to patients with advanced cancers harboring genetic alterations in ALK. In an expansion phase of the study, patients received the maximum tolerated dose. Patients were assessed to determine the safety, pharmacokinetic properties, and antitumor activity of ceritinib. Tumor biopsies were performed before ceritinib treatment to identify resistance mutations in ALK in a group of patients with NSCLC who had had disease progression during treatment with crizotinib. ResultsA total of 59 patients were enrolled in the dose-escalation phase. The maximum tolerated dose of ceritinib was 750 mg once daily; dose-l...